We provide you with 20 years of free, institutional-grade data for NERV stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NERV. Explore the full financial landscape of NERV stock.
| Reported Date | CIK | Ticker | Type |
|---|
Minerva Neurosciences, Inc(NASDAQ:NERV) 
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment o...
Website: http://www.minervaneurosciences.com
Founded: 2007
Full Time Employees: 13
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about NERV stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.